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OBJECTIVE — To compare the effect of short-term metformin and fenoﬁbrate treatment,
administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors,
and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia.
RESEARCHDESIGNANDMETHODS — Westudied128type2diabeticpatientswith
mixed dyslipidemia complying throughout the study with lifestyle intervention who were ran-
domized twice, initially to either metformin or placebo, and then to micronized fenoﬁbrate or
placebo.
RESULTS — Fenoﬁbrate alleviated diabetic dyslipidemia–induced changes in plasma high-
sensitivity C-reactive protein, ﬁbrinogen, and plasminogen activator inhibitor (PAI)-1 and in
monocyte cytokine release, whereas metformin or lifestyle intervention improved mainly glu-
cose and lipid metabolism. The strongest pleiotropic effect was observed when fenoﬁbrate was
added to metformin.
CONCLUSIONS — Fenoﬁbrate, particularly administered together with metformin, is su-
perior to metformin and lifestyle intervention in exhibiting beneﬁcial effects on systemic inﬂam-
mation, hemostasis, and monocyte secretory function in type 2 diabetic patients with mixed
dyslipidemia.
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P
eroxisome proliferator–activated re-
ceptor (PPAR)- activators (ﬁ-
brates) administered to patients
with dyslipidemia (1–4) or early glucose
metabolism abnormalities (5) produce
many non–lipid-related effects, including
anti-inﬂammatory, antioxidant, and anti-
thrombotic actions and improvement in
endothelial function. Apart from normal-
izing glucose metabolism, metformin, the
only oral antidiabetic medication shown
to decrease cardiovascular events inde-
pendent of glycemic control (6), im-
proved dyslipidemia, hemostasis, and
systemic inﬂammation (7). To the best of
ourknowledge,nopreviousclinicalstudy
has ever compared clinical beneﬁts of
metformin and ﬁbrates when it comes to
their pleiotropic effects and assessed
whether metformin-ﬁbrate combination
is superior to treatment with only one of
these drugs.
RESEARCH DESIGN AND
METHODS— The patients included
in the study met the following criteria: 1)
recently diagnosed and previously un-
treated type 2 diabetes (fasting plasma
glucose at least 126 mg/dl or plasma glu-
coseconcentration2hafteraglucoseload
at least 200 mg/dl) and 2) mixed dyslipi-
demia (plasma total cholesterol 200
mg/dl, LDL cholesterol 130 mg/dl, tri-
glycerides 150 mg/dl). The exclusion
criteria are presented in the supplemental
data, available in an online appendix at
http://care.diabetesjournals.org/cgi/content/
full/dc08-2335/DC1. The study protocol
wasapprovedbythelocalethicscommittee.
All included patients (n  128) were given
detailed advice about how to achieve the
goalsoflifestylemodiﬁcation,whichwerea
reduction in weight of 7% or more if neces-
sary, total fat intake 30% of total energy
intake, saturated fat intake 7% of energy
consumed, cholesterol intake 200 mg/
day, an increase in ﬁber intake to 15 g per
1,000 kcal, and moderate to vigorous exer-
cise for at least 30 min/day. The patients
were randomized in a double-blind fashion
to metformin (850 mg; n  66) or placebo
(n  62), which were administered twice
dailyfor60days.After30daysoftreatment,
patients of each group were again random-
ized to receive once daily at bedtime either
micronized fenoﬁbrate (267 mg daily) or
placebo, and the treatment with metfor-
min  fenoﬁbrate (n  33), metformin 
placebo (n  33), placebo  fenoﬁbrate
(n  31), or placebo  placebo (n  31)
together with lifestyle intervention were
continued for the following 30 days. All
treatment groups were compared with two
age-, sex-, and weight-matched groups of
patients: type 2 diabetic subjects with
mixed dyslipidemia (n  32) and control
normoglycemic and normolipidemic sub-
jects(n32).Patientsbelongingtobothof
these groups were brieﬂy informed about
the beneﬁts of a healthy diet but were not
prescribed any special dietary and exercise
recommendations. Lipid proﬁle, plasma
glucose, insulin, high-sensitivity C-reactive
protein (hsCRP), ﬁbrinogen, plasminogen
activator inhibitor (PAI)-1, homeostasis as-
sessment(HOMA)index,A1C,andmono-
cyte release of tumor necrosis factor
(TNF)- and interleukin-1 were deter-
mined before and after 30 and 60 days of
therapy (3,5). Statistical analysis was per-
formed as previously described (3,5).
RESULTS— At baseline, there was no
difference between the groups in terms of
sex, weight, age, medical background,
and clinical characteristics. Apart from
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DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009 1421Table 1—Effect of metformin and fenoﬁbrate, administered alone or in sequence, together with lifestyle intervention on lipid proﬁle, glucose
metabolism, low-grade inﬂammation, hemostasis, and cytokine secretion by stimulated monocytes in type 2 diabetic patients with mixed
dyslipidemia
Type 2 diabetic patients with mixed dyslipidemia complying with lifestyle intervention
Patients not complying with
lifestyle intervention
Placebo  placebo Metformin  placebo
Placebo 
fenoﬁbrate
Metformin 
fenoﬁbrate
Diabetic
dyslipidemia 
Control
subjects¶
Number of
patients
30 31 30 33 32 32
Fasting glucose
(mg/dl)
Baseline 169.1  4.4*** 168.8  4.1*** 164.5  3.1*** 165.9  3.2*** 165.8  4.6*** 90.1  2.2
After 30 days 141.0  5.6***†† 121.8  4.9***††† 139.4  3.6***† 120.5  3.1***††† 162.2  4.0*** 90.5  2.0
After 60 days 147.5  3.9***† 109.6  4.3***†††‡ 142.1  3.2***† 106.1  3.7*†††‡ 167.2  3.8*** 88.2  1.9
HOMA
Baseline 11.5  0.7*** 11.7  0.6*** 11.3  0.8*** 11.9  0.7*** 11.4  0.8*** 2.1  0.2
After 30 days 11.1  0.6*** 8.0  0.6***† 10.9  0.5*** 8.9  0.8***† 11.6  0.6*** 2.0  0.1
After 60 days 10.3  0.5***† 6.8  0.4***††† 8.7  0.6***††‡ 5.0  0.4**†††‡‡‡ 11.3  0.9*** 2.2  0.2
A1C (%)
Baseline 7.5  0.2*** 7.4  0.2*** 7.5  0.2*** 7.4  0.1*** 7.4  0.3*** 5.1  0.2
After 30 days 7.0  0.2***† 6.5  0.2***†† 7.0  0.2***† 6.5  0.2***†† 7.4  0.2*** 5.0  0.1
After 60 days 7.0  0.2***† 6.2  0.1***††† 6.7  0.2***†† 6.1  0.1**††† 7.3  0.2*** 5.1  0.2
Total cholesterol
(mg/dl)
Baseline 226.5  4.1*** 229.3  3.2*** 228.1  4.2*** 232.1  3.6*** 228.8  5.4*** 162.0  4.2
After 30 days 224.4  4.2*** 228.3  2.5*** 216.6  3.2*** 221.1  3.5*** 230.1  3.4*** 160.0  3.2
After 60 days 229.3  5.0*** 223.6  4.0*** 188.3*  4.5**††‡ 183.8  4.0*†††‡‡ 231.1  2.3*** 159.9  2.3
LDL cholesterol
(mg/dl)
Baseline 148.2  2.3*** 150.3  2.6*** 149.0  3.2*** 150.6  2.6*** 151.1  3.5*** 108.1  2.8
After 30 days 148.1  2.4*** 147.0  3.1*** 139.8  4.1*** 142.2  2.0*** 147.4  2.8*** 110.4  2.6
After 60 days 145.0  3.0*** 140.9  3.5*** 115.1  3.2†††‡ 113.4  1.9†††‡‡ 145.4  3.7*** 110.7  2.7
HDL cholesterol
(mg/dl)
Baseline 40.1  1.0*** 39.5  1.1*** 40.4  1.1*** 39.2  1.0*** 39.9  1.1*** 47.8  0.7
After 30 days 41.8  0.7*** 40.1  0.3*** 40.6  0.6*** 41.5  0.4** 39.0  1.3*** 48.0  0.6
After 60 days 42.1  0.6*** 41.0  0.3*** 43.2  0.5**†† 43.7  0.3*†† 39.2  0.6*** 47.1  0.5
Triglycerides
(mg/dl)
Baseline 206.8  6.4*** 219.6  5.2*** 214.8  6.8*** 215.9  5.5*** 214.4  8.8*** 122.4  3.2
After 30 days 193.8  6.8*** 198.6  5.1*** 204.8  5.3*** 190.6  4.5*** 212.5  8.0*** 121.1  4.0
After 60 days 181.5  8.2***† 184.5  6.0***† 166.8  7.8**††† 142.2  8.2††† 210.0  7.8*** 120.4  4.6
hsCRP (mg/l)
Baseline 3.0  0.2*** 2.9  0.2*** 2.8  0.2*** 2.9  0.2*** 2.8  0.1*** 1.0  0.1
After 30 days 2.8  0.3*** 2.5  0.2*** 2.5  0.2*** 2.7  0.2*** 2.8  0.2*** 1.0  0.2
After 60 days 2.8  0.3*** 2.2  0.1***† 1.9  0.4***† 2.0  0.2***††‡ 2.7  0.2*** 1.1  0.1
Fibrinogen (mg/
dl)
Baseline 455.0  48.1*** 474.1  32.9*** 453.5  37.6*** 469.9  18.3*** 474.2  32.1*** 296.5  22.0
After 30 days 467.8  45.1*** 440.2  49.0*** 465.1  35.4*** 443.1  54.2*** 486.0  21.0*** 285.1  23.4
After 60 days 460.5  51.6*** 436.4  29.5*** 391.2  36.7***†‡ 346.3  48.9*††‡ 475.1  27.5*** 290.3  19.8
PAI-1 (ng/ml)
Baseline 101.5  4.1*** 99.4  3.9*** 102.0  4.8*** 95.7  3.6*** 101.1  5.2*** 49.6  6.2
After 30 days 100.6  6.1*** 94.8  3.8*** 94.8  5.1*** 92.0  2.7*** 102.4  4.4*** 48.1  4.2
After 60 days 103.3  5.7*** 92.1  4.0*** 73.9  4.6***††‡ 69.8  4.5**†††‡ 100.8  4.6*** 48.9  5.1
TNF- release
(pg/ml)
Baseline 1,530.0  68.1*** 1,453.5  42.1*** 1,511.2  64.5*** 1,449.8  53.2*** 1,489.1  71.1*** 901.7  46.6
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metabolism markers, the presence of dia-
betes and dyslipidemia was associated
with higher plasma levels of hsCRP, ﬁ-
brinogen, and PAI-1 and the increased
release of both cytokines (see the supple-
mental Table, available in the online ap-
pendix). No serious adverse effects were
observed throughout the study, and 188
patientscompletedthestudy(seethesup-
plemental Results, available in the online
appendix). Fenoﬁbrate, administered
alone or added to metformin, alleviated
diabetic dyslipidemia–induced changes
in plasma hsCRP, ﬁbrinogen, and PAI-1
and in monocyte cytokine release. In
turn, metformin or lifestyle intervention
improved mainly glucose and lipid me-
tabolism (Table 1). Metformin  fenoﬁ-
brate were superior to 1) placebo 
placebo in affecting fasting glucose,
HOMA, A1C, total, LDL, and HDL cho-
lesterol, triglycerides, hsCRP, ﬁbrinogen,
PAI-1, and monocyte cytokine release; 2)
metformin  placebo in affecting HOMA,
total, LDL, and HDL cholesterol, triglyc-
erides, ﬁbrinogen, PAI-1, and cytokine
release; and 3) placebo  fenoﬁbrate
groupinaffectingfastingglucose,HOMA,
A1C, triglycerides, ﬁbrinogen, and
TNF- release. Placebo  fenoﬁbrate
were superior to 1) placebo  placebo in
reducing total and LDL cholesterol,
HOMA, hsCRP, ﬁbrinogen, PAI-1,
TNF-, and interleukin-1 release; 2)
metformin  placebo group in reducing
total, LDL, and HDL cholesterol, ﬁbrino-
gen and PAI-1, and monocyte release of
bothcytokines;but3)inferiortothelatter
groupinreducingplasmafastingglucose,
HOMA, and A1C. Metformin  placebo
were superior to placebo  placebo in
changing fasting glucose, HOMA, A1C,
and TNF- release. At baseline, there was
a weak correlation between plasma
hsCRP and baseline cytokine release; be-
tween HOMA and plasma hsCRP, ﬁbrin-
ogen, and PAI-1; as well as well as
between HOMA and cytokine release (r
values between 0.42 and 0.51; P 
0.001). Treatment-induced changes in
plasma hsCRP correlated weakly with the
changes in TNF- and interleukin-1 re-
lease (r values from 0.45 to 0.59; P 
0.001). No other correlations were found
in both baseline conditions and after
treatment (see the supplemental Results,
available in the online appendix).
CONCLUSIONS— This prospective
partiallydouble-blindplacebo-controlled
randomized study has shown that fenoﬁ-
brate exhibited a stronger effect than
metformin and nonpharmacological in-
tervention on systemic inﬂammation,
hemostasis, and monocyte secretory
function, disturbed by the presence of
type 2 diabetes and mixed dyslipidemia.
This multidirectional action of fenoﬁ-
brate, which was lipid independent and
unrelated to the improvement in insulin
sensitivity, may contribute to the beneﬁ-
cial action of PPAR- activators on the
reduction of cardiovascular events ob-
served in some (8,9), but not other (10),
clinical trials. A weaker than anticipated
(11) action of metformin may be, at least
in part, explained by all treated subjects
complyingwithlifestylemodiﬁcation,be-
cause placebo-treated patients following
the latter strategy were superior to not
complying patients in reducing plasma
glucose, HOMA, A1C, and triglycerides.
In our study, the treatment-induced
changes in glucose and lipid metabolism,
andinlow-gradeinﬂammation,hemosta-
sis, and monocyte cytokine release, were
strongest in patients treated with both of
these agents. Considering that the as-
sessed markers are regarded as cardiovas-
cular risk factors (12–14), the obtained
results suggest bringing by metformin-
ﬁbrate combination some additional bene-
ﬁts to patients with diabetic dyslipidemia.
Taking into account that statins markedly
reduce cardiovascular risk and, if toler-
ated,shouldbegiventoalltype2diabetic
patients (15), administration of met-
formin with fenoﬁbrate may be consid-
ered an alternative treatment option in
subjects in whom statin therapy is either
contraindicated or results in adverse ef-
fects, including drug interactions.
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